Advertisement

MIT and its partner Alnylam Pharmaceuticals Inc. report that they have discovered new nanoparticles that will allow for systemic delivery of RNAi-based therapeutics.

In a paper published in the Proceedings of the National Academy of Sciences, researchers at the David H. Koch Institute for Integrative Research at MIT and at Cambridge-based Alnylam (Nasdaq: ALNY) describe how they studied more than 1,500 chemically diverse nanoparticles as drug delivery vehicles. Once they reached in vivo testing, they discovered one of those “core-shell” nanoparticles showed that it delivered the RNA interference compound effectively enough to silence hepatocyte-specific Factor VII by turning off the gene that produced it.

SOURCE

Advertisement
Advertisement